Minerva Neurosciences (NERV) Enterprise Value (2013 - 2026)
Minerva Neurosciences (NERV) posted Enterprise Value of -$32.8 million for Q1 2026, up 60.24% on a QoQ basis from -$82.4 million in Q4 2025, and down 88.38% year-over-year from -$282.0 million in Q1 2025.
Minerva Neurosciences (NERV) Enterprise Value (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Enterprise Value history runs 14 years deep, the most recent figure standing at -$32.8 million for Q1 2026.
- Quarterly Enterprise Value fell 88.38% year-over-year to -$32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.8 million (down 88.38% YoY) and the FY2025 annual result came in at -$82.4 million, down 283.94% from the prior year.
- Enterprise Value was -$32.8 million for Q1 2026 at Minerva Neurosciences, up from -$82.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$12.4 million in Q3 2025 and bottomed at -$82.4 million in Q4 2025.
- A 5-year average of -$36.3 million and a median of -$34.7 million in 2022 frame the typical range for Enterprise Value.
- Peak annual rise in Enterprise Value reached 53.48% in 2025, while the deepest fall reached 283.94% in 2025.
- Minerva Neurosciences' Enterprise Value stood at -$34.7 million in 2022, then gained by 20.79% to -$27.5 million in 2023, then advanced by 21.82% to -$21.5 million in 2024, then slumped by 283.94% to -$82.4 million in 2025, then jumped by 60.24% to -$32.8 million in 2026.
- Business Quant data shows NERV's Enterprise Value at -$32.8 million in Q1 2026, -$82.4 million in Q4 2025, and -$12.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -32.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.76 Mn |
| Dec 31, 2025 | -82.40 Mn |
| Sep 30, 2025 | -12.39 Mn |
| Jun 30, 2025 | -15.35 Mn |
| Mar 31, 2025 | -17.39 Mn |
| Dec 31, 2024 | -21.46 Mn |
| Sep 30, 2024 | -26.63 Mn |
| Jun 30, 2024 | -30.98 Mn |
| Mar 31, 2024 | -34.92 Mn |
| Dec 31, 2023 | -27.45 Mn |
| Sep 30, 2023 | -47.00 Mn |
| Jun 30, 2023 | -51.90 Mn |
| Mar 31, 2023 | -36.08 Mn |
| Dec 31, 2022 | -34.66 Mn |
| Sep 30, 2022 | -40.32 Mn |
| Jun 30, 2022 | -49.85 Mn |
| Mar 31, 2022 | -55.05 Mn |
| Dec 31, 2021 | -60.86 Mn |
| Sep 30, 2021 | -65.69 Mn |
| Jun 30, 2021 | -74.31 Mn |